- Research article
- Open Access
- Open Peer Review
Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines
© Abe et al; licensee BioMed Central Ltd. 2011
- Received: 4 August 2010
- Accepted: 1 February 2011
- Published: 1 February 2011
CD26 (dipeptidyl peptidase IV, DPPIV) is a 110 kDa surface glycoprotein expressed in most normal tissues, and is a potential novel therapeutic target for selected cancers. Our work evaluates the mechanism involved in confluence-dependent CD26 expression in colon cancer.
Colon adenocarcinoma cells were grown to confluence, and expression of CD26 and transcription factors implicated in its regulation was confirmed by immunofluorescence and Western blotting. Real-time PCR was also performed to evaluate CD26 upregulation at the transcriptional level. The influence of c-Myc on CD26 expression during different growth conditions was further evaluated following transient transfection of a c-Myc-expressing plasmid and a c-Myc specific siRNA.
We found that the colon cancer cell lines HCT-116 and HCT-15 exhibited a confluence-dependent increase in CD26 mRNA and protein, associated with decreased expression of c-Myc, increased USF-1 and Cdx 2 levels, and unchanged HNF-1α expression. Meanwhile, ectopic expression of c-Myc in both cell lines led to decreased CD26 expression. In contrast, transfection of a siRNA targeted to Cdx2 resulted in decreased CD26 level. Importantly, culturing of cells in serum-depleted media, but not acidic conditions, upregulated CD26. While HIF-1α level also increased when cells were cultured in serum-depleted media, its expression was required but not sufficient for CD26 upregulation.
CD26 mRNA and protein levels increase in a confluence-dependent manner in colon carcinoma cell lines, with c-Myc acting as a repressor and Cdx2 acting as an enhancer of CD26 expression. The enhanced expression of CD26 in serum-depleted media and a requirement for HIF-1α suggest a role for nutrients or growth factors in the regulation of CD26 protein expression.
- CD26 Expression
- Malignant Mesothelioma
- CD26 Promoter
- Fetal Bovine Serum Medium
- CD26 Protein Expression
CD26/dipeptidyl peptidase IV is a 110 kDa surface glycoprotein with diverse functional properties which include peptidase activity and functional and physical association with key molecules in various signal transduction pathways [1, 2]. During the past decades, CD26 has been shown to participate in T-cell biology as a costimulatory molecule able to regulate signaling transduction pathways [3–5]. In addition to its role in T-cell biology, recent studies have shown that CD26 also plays an important role in tumor biology.
Furthermore, CD26 itself may be a novel therapeutic target. Anti-CD26 monoclonal antibody (mAb) treatment results in both in vitro and in vivo antitumor activity against several tumor types, including lymphoma, mesothelioma and renal cell carcinoma [6–8].
However, CD26 expression varies among different cell lines and tumor histologies, resulting in conflicting reports regarding the role of CD26 in the development of different neoplasms, including colon cancer . For example, CD26 is upregulated during enterocytic differentiation of the colon adenocarcinoma cell lines Caco-2 and HT-29 . Interestingly, trypsinizing and seeding late post-confluent Caco-2 cells led to reduced CD26 expression and dipeptidyl peptidase IV activity, as well as the disappearance of other differentiation markers such as sucrase isomaltase and GLUT5 . However, the precise mechanism responsible for this cell density-dependent regulation of CD26 expression and dipeptidyl peptidase IV activity has not been fully elucidated. Compared with most normal tissues, solid tumors tend to exhibit high cell density due to rapid growth, and high cell density has been linked to anti-cancer drug resistance [11, 12]. In view of the emerging role of CD26 as a novel therapeutic target, we investigated the mechanism of confluence-dependent expression of CD26 to further understand CD26 biology.
In this paper, we investigated the mechanism involved in the confluence-dependent increase in CD26 expression in the colon cancer cell lines HCT-116 and HCT-15. We demonstrated that c-Myc is involved in the regulation of CD26 expression as a repressor of transcription in both cell lines, and that Cdx2 significantly contributes to the confluence-dependent increase in CD26 expression in HCT-15 cells. Furthermore, we found that serum-depleted culture conditions, but not acidic conditions, significantly upregulated CD26 levels, hence implicating a potential role for nutrients or serum growth factors in the regulation of CD26 protein expression.
The human colorectal carcinoma cell lines HCT-116 and HCT-15 were purchased from the American Type Culture Collection (ATCC, Manassas, VA). HCT 15, HCT-116, and HCT-116 HIF1α-/- cells  were maintained in McCoy's 5A medium (ATCC) supplemented with 10% fetal bovine serum (FBS) (Hyclone, South Logan, Utah), 100 units/ml of penicillin and 100 μg/ml of streptomycin (Invitrogen) at 37°C and 5% CO2. For confluence-dependent experiments, HCT-116 cells or HCT-15 cells were seeded at 7.5 × 105 cells/6-cm dish and 1.0 × 106 cells/6-cm dish (day-0), respectively, and were grown several days to obtain a post-confluent state. Medium was changed daily. For immunofluorescence staining, cells were grown on a glass slide in RPMI-1640 (Hyclone) without phenol red and supplemented with 10% FBS, 100 units/ml of penicillin, and 100 μg/ml of streptomycin at 37°C. Cells were cultured at sub-confluence or post-confluence by changing medium daily. For normoxic culture conditions, cells were incubated at 37°C, in 5% CO2 and room air (21% O2). For hypoxic conditions, cells were incubated at 37°C in a hypoxia chamber (Billups-Rothenberg, Del Mar, CA) flushed and equilibrated with 1% O2, 94% N2 and 5% CO2 (Airgas West, Las Vegas, NV). For acidic culture conditions, cells were cultured in McCoy's 5A medium supplemented with 25 mM 2-N-morpholine ethanesulfonic acid (MES, Sigma, St Louis, MO) and 10% FBS (pH 6.2) under normoxic or hypoxic conditions. For hypoxic or acidic culture conditions, cells were used at 3 days post-confluence, and grown on the bottom of a standing flask (25 cm2) filled with 50 ml of culture medium to avoid any change in pH or serum concentration. For serum depletion experiments, cells were cultured in McCoy's 5A medium containing 0.3% bovine serum albumin (BSA, Sigma).
Cells were lysed with RIPA buffer [1% NP40, 0.5% deoxycholate, 0.1% SDS, 150 mM sodium chloride, 50 mM Tris-HCl (pH 8.0)] supplemented with Halt protease inhibitor cocktail (Pierce, Rockford, IL), 5 mM EDTA, 5 mM sodium orthovanadate, 10 mM sodium fluoride and 1 mM β-glycerophosphate (Sigma). For preparation of lysates from cells cultured under hypoxic conditions, 100 μM CoCl2 was added to the lysis buffer to prevent degradation of HIF-1α. Protein concentration was measured by Micro BCA Protein Assay Kit (Pierce). Lysates were mixed with Laemmli sample buffer (4X), boiled for 5 minutes at 100°C, and equal amounts of protein (50 μg per lane for a 10 comb gel) were separated by SDS-PAGE, followed by overnight wet-transfer to nitrocellulose at 4°C. For detection of CD26, samples were incubated at a lower temperature (37°C for 15 min). CD26 was detected at 220 kDa as a form of homodimer which increased detection sensitivity . We confirmed that the band detected at 220 kDa was depleted in a dose-dependent manner with anti-CD26 mouse monoclonal antibody 1F7 by immunoprecipitation (data not shown). After blocking with 5% nonfat milk in 0.1% Tween 20-TBS for 1 hour at room temperature, membranes were incubated with the appropriate primary antibodies in 1% blocking buffer for 2 hours at room temperature or overnight at 4°C [anti-CD26 (MI1004, Calbiochem, San Diego, CA or AF1180, R&D Systems, Minneapolis, MN), anti-Cdx2 (MU392A-UC, BioGenex, San Ramon, CA), anti-α-tubulin (T9026, Sigma, Saint Louis, MO), anti-c-Myc (9E10), anti-USF-1 (C-20), anti-HNF-1α (C-19) (sc-40, sc-229, and sc-6547, respectively, Santa Cruz, Santa Cruz, CA)], anti-HIF-1α (610958, BD Transduction Laboratories, San Jose, CA)], followed by incubation with the appropriate HRP-conjugated secondary antibodies (Pierce) for 1 hour at room temperature. Membranes were incubated with SuperSignal West Dura (Pierce) for 5 minutes, and visualized using a KODAK Image Station 2000R or 4000R (Carestream Health, New Haven, CT). Some membranes were processed using the Odyssey Infrared Imaging System by using the appropriate infrared-labeled secondary antibodies in Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE).
Real-time quantitative PCR for CD26 mRNA expression
Total RNA was isolated from cells with RNeasy Mini Kit and QIAshredder (Qiagen, Valencia, CA). Equal amounts of total RNA (90 ng) were analyzed by one step real-time PCR using QuantiFast SYBR Green RT-PCR and Hs_DPP4_1_SG QuantiTect Primer Assay (Qiagen) with the Thermal Cycler 7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA). The reaction conditions were as follows: 10 minutes at 50°C (RT step), 5 minutes at 95°C, and 40 cycles of 10 seconds at 95°C followed by 30 seconds at 60°C. Relative changes in CD26 mRNA expression were calculated based on the 2-ΔCT method .
Following washing with PBS, cells were fixed with cold ethanol for 2 min. Cells were air-dried, rehydrated with PBS, and blocked with 5% BSA in PBS for 30 minutes at room temperature. After washing with PBS for 3 minutes (3 times), cells were incubated with anti-CD26 mouse mAb (202.36, Santa Cruz) for 1 hour at room temperature. Cells were then washed with PBS and incubated with fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (F8264, Sigma) for 30 minutes in the dark at room temperature. After washing with PBS, cells were mounted using Fluoroguard™ Antifade (Insitus Biotechnologies, Albuquerque, NM) and immunofluorescence was visualized using a fluorescence microscope (Olympus-BX51, Melville, NY).
Transient transfection for ectopic expression of c-Myc
Confluent HCT-116 and HCT-15 cells (95-100% confluence) in 6-well plates were transfected with 5 μg/well of pcDNA3-c-Myc (provided by Dr. Wafik El-Deiry, University of Pennsylvania, through Addgene as a distributor, Cambridge, MA) or empty vector using 10 μl/well of Lipofectamine 2000. Cells were grown for several days, and medium was changed daily.
Transient transfection of Cdx-2 siRNA
HCT-15 cells were grown to 80-90% confluence in 6-well plates and were transfected with 200 pmol/well of Cdx-2 siRNA (sc-43680, Santa Cruz) or control siRNA (sc-37007, Santa Cruz) using 7 μl per well of Lipofectamine 2000 (Invitrogen). Medium was changed daily.
Confluence-dependent upregulation of CD26 expression in HCT-116 and HCT-15 cells
Confluence-dependent expression of transcription factors c-Myc, USF-1, HNF-1α, and Cdx2 in HCT-116 and HCT-15 cells
We also examined the expression of the proto-oncogene c-Myc in this process. A transcription factor belonging to the basic helix-loop-helix leucine zipper transcription factor family, c-Myc is closely linked to upregulated proliferation and deregulated cell cycle in tumors . c-Myc is known to bind to specific DNA sequences referred to as E-box sequences. USF-1 can also bind to these sequences, and in fact, c-Myc and USF-1 have been reported to exert opposing effects on promoter activity for some genes by competing with each other to occupy E-box sites . In addition, c-Myc has been reported to suppress gene expression of proteins involved in differentiation and cell cycle arrest such as p15Ink4b, p21Cip1 and p27Kip1. We now demonstrate that, unlike our findings with USF-1, c-Myc expression decreases in a confluence-dependent manner in both cell lines (Figure 2), suggesting the involvement of c-Myc as a negative regulator of CD26 expression.
Cdx2 is a member of the caudal-related homeobox gene family and has emerged as one of the major regulatory factors controlling intestinal cell differentiation . Previous work has indicated that the forced expression of Cdx2 in HIEC cells (a normal human intestinal epithelial crypt cell model) led to CD26 upregulation . However, Cdx2 can be phosphorylated by cyclin-dependent kinase 2 (Cdk2), resulting in ubiquitin-dependent degradation . Therefore, the increased CD26 expression in HIEC cells was found to be limited by Cdx2 degradation by proteosomes. In our studies, there was a dramatic increase in Cdx2 protein expression in a confluence-dependent manner in HCT-15 cells. However Cdx2 was undetectable in HCT-116 cells at all states of confluence (Figure 2).
Involvement of c-Myc as a repressor of CD26 expression in HCT-116 and HCT-15 cells
Involvement of Cdx2 in the confluence-dependent increase in CD26 expression in HCT-15 cells
To evaluate the effect of ectopic expression of Cdx2 on CD26 level, we transiently transfected Cdx2 into HCT-116 and HCT-15 cells at various states of confluence. However, we found no significant effect on CD26 expression in either cell line (data not shown). One potential explanation for these findings is that Cdx2 may exert its effect on the CD26 promoter by combining with an unknown factor X. Therefore, decreasing Cdx2 level by siRNA would reduce the putative Cdx2-factor X complex, leading to a lowered CD26 promoter activity. This scenario may explain the lack of effect on CD26 transcription following transient transfection of Cdx2 alone (without increasing factor X).
Effect of hypoxic, acidic and serum-depleted culture conditions on CD26 expression in HCT-116 cells
We next examined whether low extracellular pH affected CD26 protein expression. HCT-116 cells at post-confluence or sub-confluence were cultured in regular 10% FBS medium at pH 7.3 or acidic 10% FBS medium supplemented with 25 mM MES at pH 6.2. As shown in Figure 5E and 5F, the pH of the medium did not affect CD26 expression in sub-confluent or post-confluent cultures.
Since nutrients and serum growth factors may be depleted when cells reach a high cell density, we also tested the effect of culturing cells in serum-depleted media. Since the supply of available nutrients and growth factors may vary in post-confluent cultures, the use of serum-depleted media may offer a more consistent culture environment to evaluate the role of nutrients and serum growth factors in CD26 expression. When HCT-116 cells at sub-confluence were cultured in 0.3% BSA medium without serum for 24 hours, CD26 protein level was significantly increased compared to cells cultured in 10% FBS medium (Figure 5F and 5G). HIF-1α level was likewise increased when cells were cultured in the absence of serum (Figure 5G). On the other hand, c-Myc expression was decreased in serum-depleted media. Interestingly, CD26 expression in cells cultured for 24 hours with 10% FBS (following 24-hour serum depletion) returned to basal level as did HIF1-α and c-Myc (Figure 5G), demonstrating the reversibility of this phenomena.
In the present study, we demonstrate that CD26 expression is increased in colon carcinoma lines grown to confluence, associated with changes in selected transcription factors. In particular, we found that c-Myc expression decreases with confluence, and that it can act as a repressor of CD26 expression. In contrast, Cdx2 expression parallels that of CD26, increasing with confluence. A potential explanation for the observed confluence-dependent increase in Cdx2 protein expression may be due to confluence-mediated cell cycle arrest, resulting in decreased expression of Cdk2 and decreased phosphorylation of Cdx2 by Cdk2, leading to increased Cdx2 protein expression . Our findings also suggest the existence of a co-factor X that has a role in regulating CD26 expression in combination with Cdx2, although additional studies will need to be done to test this hypothesis. In addition, we demonstrated that a hypoxia-induced increase in HIF-1α was not associated with an enhanced CD26 level, but that HIF-1α expressing cells displayed a higher level of HIF-1α along with a higher level of CD26 when grown to confluence. In comparison, a lack of enhancement of HIF-1α and CD26 levels in HCT-116 HIF1α-/- cells, suggest that HIF-1α expression is required but not sufficient for increased expression of CD26.
The growth of tumors is known to be associated with hypoxia and low extracellular pH in the tumor microenvironment . In our experimental system, low extracellular pH had no effect on CD26 protein expression, regardless of the extent of cell confluence. On the other hand, we found that depletion of serum factors was associated with a robust upregulation of CD26. Furthermore, the effect of serum depletion on CD26 protein expression was reversible, as was also the case with c-Myc and HIF-1α expression. All three proteins returned to basal level of expression in 24 hours following culturing in regular 10% FBS medium. These results hence suggest that there is a serum factor(s)-dependent regulatory mechanism for CD26 protein expression, which affects cells maintained without serum at sub-confluence. Since the half life of CD26 protein in cells at post-confluence is reported to be much longer than 48 hours as assayed by [35S]-methionine label pulse-chase experiments , our results suggest the existence of an unidentified serum factor-dependent degradative mechanism in the regulation of CD26 protein expression. These data indicate that a post-confluent state can be mimicked by cells at sub-confluence by depleting required serum factors. While we did not detect differences in CD26 expression when cells were incubated in serum-free conditions with low levels of BSA (data not shown), it is still theoretically possible that the presence of BSA in the culture media of cells cultured in serum-free conditions can interfere with CD26 metabolism and expression. We would also like to note that our observations are restricted to the specific cells and proteins evaluated in our experimental conditions, and are not necessarily applicable to other cell types or proteins. When cells are at post-confluence, depletion of nutrients is likely to limit cell growth. In addition, tight junctions between cells growing at post-confluence may inhibit binding of serum factors to the cell surface, leading to the upregulation of CD26. However, the potential contribution of factors secreted from cells at post-confluence cannot be excluded. In fact, others have reported increased HIF-1α expression when sub-confluent breast carcinoma cells were incubated with conditioned media from confluent cultures .
Our previous studies demonstrated the potential of targeted therapy using anti-CD26 mAb treatment in several tumor models, including renal clear cell carcinoma and malignant mesothelioma [7, 8]. In these cell lines, upregulation of p27Kip1 was observed following treatment with anti-CD26 mAb. We observed that p27Kip1 expression was elevated in cells treated with anti-CD26 mAb compared to isotype-matched control mAb when treatment was done in serum-depleted culture conditions (data not shown). However, this anti-CD26 mAb-mediated enhancement in p27Kip1 level was not observed if cells were incubated in serum-containing media, indicating that serum depletion can enhance the effect of anti-CD26 mAb treatment in cells normally expressing low CD26 level (presumably by upregulating target expression). Future studies will examine in detail the mechanism associated with CD26 enhancement mediated by serum-depleted culture conditions. This knowledge, combined with our present findings, may prove to have clinical significance by expanding the potential usage of anti-CD26 mAb therapy in selected human cancers through enhanced CD26 expression.
In summary, we demonstrate that CD26 expression is regulated in a confluence-dependent manner, involving potentially transcriptional and posttranslational mechanisms. For the confluence-dependent increase in CD26 expression, decreased expression of c-Myc and increased expression of USF-1 and Cdx2 may contribute to the upregulation of CD26 expression at the transcriptional level. Meanwhile, factors associated with serum depletion may also contribute to increased CD26 expression, with one potential mechanism being at the posttranslational level by regulating an unknown serum factor-dependent CD26 protein degradation pathway. Importantly, our present findings may result in the expansion of the use of CD26-targeted therapy in the clinical setting for selected tumors by regulating the expression of CD26 itself.
- Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH: The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008, 13: 1634-1645. 10.2741/2787.View ArticlePubMedGoogle Scholar
- Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH: CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem. 2007, 7: 253-273. 10.2174/138955707780059853.View ArticlePubMedGoogle Scholar
- Sato K, Aytac U, Yamochi T, Ohnuma K, McKee KS, Morimoto C, Dang NH: CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors. Br J Cancer. 2003, 89: 1366-1374. 10.1038/sj.bjc.6601253.View ArticlePubMedPubMed CentralGoogle Scholar
- Sato T, Yamochi T, Aytac U, Ohnuma K, McKee KS, Morimoto C, Dang NH: CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 2005, 65: 6950-6956. 10.1158/0008-5472.CAN-05-0647.View ArticlePubMedGoogle Scholar
- Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K, McKee KS, Morimoto C, Dang NH: Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Res. 2005, 65: 1973-1983. 10.1158/0008-5472.CAN-04-2611.View ArticlePubMedGoogle Scholar
- Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, et al: In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res. 2001, 7: 2031-2040.PubMedGoogle Scholar
- Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, et al: Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res. 2007, 13: 4191-4200. 10.1158/1078-0432.CCR-07-0110.View ArticlePubMedGoogle Scholar
- Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tachibana M, Katsuoka Y, Dang NH, Morimoto C: Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res. 2006, 12: 3470-3477. 10.1158/1078-0432.CCR-06-0361.View ArticlePubMedGoogle Scholar
- Darmoul D, Lacasa M, Baricault L, Marguet D, Sapin C, Trotot P, Barbat A, Trugnan G: Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992, 267: 4824-4833.PubMedGoogle Scholar
- Pandrea IV, Carriere V, Barbat A, Cambier D, Dussaulx E, Lesuffleur T, Rousset M, Zweibaum A: Postmitotic differentiation of colon carcinoma caco-2 cells does not prevent reentry in the cell cycle and tumorigenicity. Exp Mol Pathol. 2000, 69: 37-45. 10.1006/exmp.2000.2309.View ArticlePubMedGoogle Scholar
- Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M, Dimanche-Boitrel MT: Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. Int J Cancer. 1995, 61: 873-879. 10.1002/ijc.2910610621.View ArticlePubMedGoogle Scholar
- Fang Y, Sullivan R, Graham CH: Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res. 2007, 313: 867-877. 10.1016/j.yexcr.2006.12.004.View ArticlePubMedGoogle Scholar
- Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV, Dang LH: Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res. 2006, 66: 1684-1936. 10.1158/0008-5472.CAN-05-2887.View ArticlePubMedGoogle Scholar
- Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT: Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 2002, 277: 29231-29241. 10.1074/jbc.M202770200.View ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Erickson RH, Lai RS, Kim YS: Role of hepatocyte nuclear factor 1alpha and 1beta in the transcriptional regulation of human dipeptidyl peptidase IV during differentiation of Caco-2 cells. Biochem Biophys Res Commun. 2000, 270: 235-239. 10.1006/bbrc.2000.2420.View ArticlePubMedGoogle Scholar
- Erickson RH, Lai RS, Lotterman CD, Kim YS: Identification of upstream stimulatory factor as an activator of the human dipeptidyl peptidase IV gene in Caco-2 cells. Gene. 2000, 258: 77-84. 10.1016/S0378-1119(00)00422-4.View ArticlePubMedGoogle Scholar
- Sawadogo M, Van Dyke MW, Gregor PD, Roeder RG: Multiple forms of the human gene-specific transcription factor USF. I. Complete purification and identification of USF from HeLa cell nuclei. J Biol Chem. 1988, 263: 11985-11993.PubMedGoogle Scholar
- Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR: Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science. 1987, 238: 688-692. 10.1126/science.3499668.View ArticlePubMedGoogle Scholar
- Vita M, Henriksson M: The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006, 16: 318-330. 10.1016/j.semcancer.2006.07.015.View ArticlePubMedGoogle Scholar
- Al-azzeh E, Dittrich O, Vervoorts J, Blin N, Gott P, Luscher B: Gastroprotective peptide trefoil factor family 2 gene is activated by upstream stimulating factor but not by c-Myc in gastrointestinal cancer cells. Gut. 2002, 51: 685-690. 10.1136/gut.51.5.685.View ArticlePubMedPubMed CentralGoogle Scholar
- Gartel AL, Shchors K: Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res. 2003, 283: 17-21. 10.1016/S0014-4827(02)00020-4.View ArticlePubMedGoogle Scholar
- Silberg DG, Swain GP, Suh ER, Traber PG: Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000, 119: 961-971. 10.1053/gast.2000.18142.View ArticlePubMedGoogle Scholar
- Escaffit F, Pare F, Gauthier R, Rivard N, Boudreau F, Beaulieu JF: Cdx2 modulates proliferation in normal human intestinal epithelial crypt cells. Biochem Biophys Res Commun. 2006, 342: 66-72. 10.1016/j.bbrc.2006.01.128.View ArticlePubMedGoogle Scholar
- Boulanger J, Vezina A, Mongrain S, Boudreau F, Perreault N, Auclair BA, Laine J, Asselin C, Rivard N: Cdk2-dependent phosphorylation of homeobox transcription factor CDX2 regulates its nuclear translocation and proteasome-mediated degradation in human intestinal epithelial cells. J Biol Chem. 2005, 280: 18095-18107. 10.1074/jbc.M502184200.View ArticlePubMedGoogle Scholar
- Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Cruz-Correa M, et al: Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res. 2008, 68: 1872-1880. 10.1158/0008-5472.CAN-07-1589.View ArticlePubMedGoogle Scholar
- Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, Odegard KC, Laussen PC, Thompson LF, Colgan SP: Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood. 2006, 108: 1602-1610. 10.1182/blood-2006-02-001016.View ArticlePubMedPubMed CentralGoogle Scholar
- Sato Y, Fujiwara H, Higuchi T, Yoshioka S, Tatsumi K, Maeda M, Fujii S: Involvement of dipeptidyl peptidase IV in extravillous trophoblast invasion and differentiation. J Clin Endocrinol Metab. 2002, 87: 4287-4296. 10.1210/jc.2002-020038.View ArticlePubMedGoogle Scholar
- Tredan O, Galmarini CM, Patel K, Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007, 99: 1441-1454. 10.1093/jnci/djm135.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/11/51/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.